Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more

BioCentury’s weekly roundup of biopharma deals, Jan. 16-22

January 23, 2024 1:32 AM UTC

The decision by Coherus BioSciences Inc. (NASDAQ:CHRS) to divest eye disease therapy Cimerli, a biosimilar of ranibizumab, will further sharpen the biotech’s focus on its core area of oncology.  Sandoz Group AG (SIX:SDZ; Pink:SDZNY) agreed to purchase the asset for $170 million in upfront cash.

The deal, which is expected to close this half, is part of Coherus’ plan to monetize its non-core assets to pay down debt, reduce interest costs and narrow its therapeutic focus. The divestiture will also reduce headcount and overhead costs, the company said. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article